Citations (69)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Paraskevi Panagopoulou & Emmanuel Roilides. (2022) Evaluating posaconazole, its pharmacology, efficacy and safety for the prophylaxis and treatment of fungal infections. Expert Opinion on Pharmacotherapy 23:2, pages 175-199.
Read now
Read now
Pauline L Jacinto & Pranatharthi Chandrasekar. (2013) Safety of posaconazole
. Expert Opinion on Drug Safety 12:2, pages 265-274.
Read now
Read now
Pierre Charles, Jean-Emmanuel Kahn, Felix Ackermann, Patrick Honderlick & Olivier Lortholary. (2013) Renal mucormycosis complicating extracorporeal membrane oxygenation. Medical Mycology 51:2, pages 193-195.
Read now
Read now
Anne M. Baciewicz, Cary R. Chrisman, Christopher K. Finch & Timothy H. Self. (2013) Update on rifampin, rifabutin, and rifapentine drug interactions. Current Medical Research and Opinion 29:1, pages 1-12.
Read now
Read now
Werner J. Heinz, Anna Grau, Anne Ulrich, Annegret Helle-Beyersdorf, Janina Zirkel, Diana Schirmer, Ulrike Lenker, Hermann Einsele & Hartwig Klinker. (2012) Impact of benzodiazepines on posaconazole serum concentrations. A population-based pharmacokinetic study on drug interaction. Current Medical Research and Opinion 28:4, pages 551-557.
Read now
Read now
Paul O Gubbins. (2011) Triazole antifungal agents drug–drug interactions involving hepatic cytochrome P450. Expert Opinion on Drug Metabolism & Toxicology 7:11, pages 1411-1429.
Read now
Read now
Emily Zoller, Connie Valente, Kyle Baker & Michael E Klepser. (2010) Development, clinical utility, and place in therapy of posaconazole for prevention and treatment of invasive fungal infections. Drug Design, Development and Therapy 4, pages 299-311.
Read now
Read now
Winter J Smith, Richard H Drew & John R Perfect. (2009) Posaconazole’s impact on prophylaxis and treatment of invasive fungal infections: an update. Expert Review of Anti-infective Therapy 7:2, pages 165-181.
Read now
Read now
Articles from other publishers (61)
John O. Miners, Thomas M. Polasek, Julie-Ann Hulin, Andrew Rowland & Robyn Meech. (2023) Drug-drug interactions that alter the exposure of glucuronidated drugs: Scope, UDP-glucuronosyltransferase (UGT) enzyme selectivity, mechanisms (inhibition and induction), and clinical significance. Pharmacology & Therapeutics 248, pages 108459.
Crossref
Crossref
Takashi Iwasa, Camila de Almeida, Floris Fauchet, Gregory A. Winchell, Rik de Greef, Chihiro Hasegawa, Hiroyuki Yoshitsugu & Rebecca Ellen Wrishko. (2022) Model‐Informed Dose Justifications of Posaconazole in Japanese Patients for Prophylaxis and Treatment Against Fungal Infection. The Journal of Clinical Pharmacology 63:4, pages 421-434.
Crossref
Crossref
Matt Mason, Eric Gregory, Keith Foster, Megan Klatt, Sara Zoubek & Albert J Eid. (2022)
Pharmacologic Management of
Mycobacterium chimaera
Infections: A Primer for Clinicians
. Open Forum Infectious Diseases 9:7.
Crossref
Crossref
Sonia Vu, Nicolas Belaube, Ana Canestri, Michel Develoux, Alicia Moreno, Eric Fourniols, Minh Patrick Lê, Ludovic Lassel, Gilles Pialoux & Ruxandra Calin. (2021) A case of tuberculosis and black-grain eumycetoma co-infection in a non-endemic country: clinical presentation and therapeutic management. International Journal of Infectious Diseases 112, pages 186-188.
Crossref
Crossref
Nicholas Power, Fiona Lynch, David W. Denning & Rohit Bazaz. (2020) Attainment of therapeutic posaconazole serum levels during co-administration with rifampicin. Journal of Global Antimicrobial Resistance 23, pages 284-285.
Crossref
Crossref
Po-Chang Chiang, Karthik Nagapudi, Michael J. Dolton & Jia Liu. (2020) Exploring Multicompartment Plug Flow–Based Model Approach in Biopharmaceutics: Impact of Stomach Setting and the Estimation of the Fraction Absorbed of Orally Administered Basic Drugs. Journal of Pharmaceutical Sciences 109:3, pages 1261-1269.
Crossref
Crossref
William L. Marshall, Jacqueline B. McCrea, Sreeraj Macha, Karsten Menzel, Fang Liu, Arne van Schanke, Joanna I. Udo de Haes, Azra Hussaini, Heather R. Jordan, Melissa Drexel, Bhavna S. Kantesaria, Christine Tsai, Carolyn R. Cho, Ellen G. J. Hulskotte, Joan R. Butterton & Marian Iwamoto. (2018) Pharmacokinetics and Tolerability of Letermovir Coadministered With Azole Antifungals (Posaconazole or Voriconazole) in Healthy Subjects. The Journal of Clinical Pharmacology 58:7, pages 897-904.
Crossref
Crossref
Sam Maleki, Carmela Corallo, John Coutsouvelis & Jasmine Singh. (2016) Failure to achieve therapeutic levels with high-dose posaconazole tablets potentially due to enhanced clearance. Journal of Oncology Pharmacy Practice 24:1, pages 63-66.
Crossref
Crossref
Jarrett R. Amsden & Paul O. Gubbins. 2018. Drug Interactions in Infectious Diseases: Antimicrobial Drug Interactions. Drug Interactions in Infectious Diseases: Antimicrobial Drug Interactions
425
501
.
Holger Petri. (2017) Arzneimitteltherapiesicherheit: Interaktionspotenzial der Azol-Antimykotika. Deutsches Ärzteblatt Online.
Crossref
Crossref
Yoann Crabol, Emilie Catherinot, Nicolas Veziris, Vincent Jullien & Olivier Lortholary. (2016) Rifabutin: where do we stand in 2016?. Journal of Antimicrobial Chemotherapy 71:7, pages 1759-1771.
Crossref
Crossref
Stefanie Hennig, Elin M. Svensson, Ronald Niebecker, P. Bernard Fourie, Marc H. Weiner, Stefano Bonora, Charles A. Peloquin, Keith Gallicano, Charles Flexner, Alex Pym, Peter Vis, Piero L. Olliaro, Helen McIlleron & Mats O. Karlsson. (2016) Population pharmacokinetic drug–drug interaction pooled analysis of existing data for rifabutin and HIV PIs. Journal of Antimicrobial Chemotherapy 71:5, pages 1330-1340.
Crossref
Crossref
R Andres Floto, Kenneth N Olivier, Lisa Saiman, Charles L Daley, Jean-Louis Herrmann, Jerry A Nick, Peadar G Noone, Diana Bilton, Paul Corris, Ronald L Gibson, Sarah E Hempstead, Karsten Koetz, Kathryn A Sabadosa, Isabelle Sermet-Gaudelus, Alan R Smyth, Jakko van Ingen, Richard J Wallace, Kevin L Winthrop, Bruce C Marshall & Charles S Haworth. (2016) US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. Thorax 71:Suppl 1, pages i1-i22.
Crossref
Crossref
. 2016. Meyler's Side Effects of Drugs. Meyler's Side Effects of Drugs
132
170
.
Simon Leung, Mara Poulakos & Jade Machin. (2015) Posaconazole: An Update of Its Clinical Use. Pharmacy 3:4, pages 210-268.
Crossref
Crossref
Anne Poon & Lowan K. Ly. 2015. Thomas’ Hematopoietic Cell Transplantation. Thomas’ Hematopoietic Cell Transplantation
1206
1217
.
Stephanie Flowers & P Rogers. 2015. Practical Handbook of Microbiology, Third Edition. Practical Handbook of Microbiology, Third Edition
183
196
.
Anthony J. Guarascio & Douglas Slain. (2015) Review of the New Delayed-Release Oral Tablet and Intravenous Dosage Forms of Posaconazole. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 35:2, pages 208-219.
Crossref
Crossref
Seong Mi Moon, Hye Yun Park, Byeong-Ho Jeong, Kyeongman Jeon, Soo-Youn Lee & Won-Jung Koh. (2015) Effect of Rifampin and Rifabutin on Serum Itraconazole Levels in Patients with Chronic Pulmonary Aspergillosis and Coexisting Nontuberculous Mycobacterial Infection. Antimicrobial Agents and Chemotherapy 59:1, pages 663-665.
Crossref
Crossref
M. M. Chau, D. C. M. Kong, S. J. van Hal, K. Urbancic, J. A. Trubiano, M. Cassumbhoy, J. Wilkes, C. M. Cooper, J. A. Roberts, D. J. E. Marriott & L. J. Worth. (2014) Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014. Internal Medicine Journal 44:12b, pages 1364-1388.
Crossref
Crossref
Michael J. Dolton, Roger J. M. Brüggemann, David M. Burger & Andrew J. McLachlan. (2014) Understanding Variability in Posaconazole Exposure Using an Integrated Population Pharmacokinetic Analysis. Antimicrobial Agents and Chemotherapy 58:11, pages 6879-6885.
Crossref
Crossref
Ximena Millan, Victoria Muggia & Belinda Ostrowsky. 2014. Infectious Complications in Cancer Patients. Infectious Complications in Cancer Patients
413
462
.
José A. Paiva & José M. Pereira. (2013) New antifungal antibiotics. Current Opinion in Infectious Diseases 26:2, pages 168-174.
Crossref
Crossref
Michael J. Dolton, John E. Ray, Sharon C.-A. Chen, Kingsley Ng, Lisa Pont & Andrew J. McLachlan. (2012) Multicenter Study of Posaconazole Therapeutic Drug Monitoring: Exposure-Response Relationship and Factors Affecting Concentration. Antimicrobial Agents and Chemotherapy 56:11, pages 5503-5510.
Crossref
Crossref
Werner J. Heinz & Hartwig Klinker. (2012) Therapeutic drug monitoring of antifungal agents. Laboratoriumsmedizin 36:2, pages 1-10.
Crossref
Crossref
Michael J. Dolton, John E. Ray, Deborah Marriott & Andrew J. McLachlan. (2012) Posaconazole Exposure-Response Relationship: Evaluating the Utility of Therapeutic Drug Monitoring. Antimicrobial Agents and Chemotherapy 56:6, pages 2806-2813.
Crossref
Crossref
Aspasia Katragkou, Fotini Tsikopoulou, Emmanuel Roilides & Theoklis E. Zaoutis. (2011) Posaconazole: when and how? The clinician’s view. Mycoses 55:2, pages 110-122.
Crossref
Crossref
Susan J Howard, Timothy W Felton, Alicia Gomez-Lopez & William W Hope. (2012) Posaconazole: The Case for Therapeutic Drug Monitoring. Therapeutic Drug Monitoring 34:1, pages 72-76.
Crossref
Crossref
Joseph E. WooleryEric WombwellMyke R. Green. (2012) Posaconazole for the Treatment of Oropharyngeal Candidiasis, Including Triazole-Resistant Disease, in HIV-positive patients. Clinical Medicine Insights: Therapeutics 4, pages CMT.S5434.
Crossref
Crossref
Werner J. Heinz & Hartwig Klinker. (2012) Therapeutisches Drug Monitoring von Antimykotika/Therapeutic drug monitoring of antifungal agents. LaboratoriumsMedizin 36:2.
Crossref
Crossref
Cornelia Lass-Flörl. (2011) Triazole Antifungal Agents in Invasive Fungal Infections. Drugs 71:18, pages 2405-2419.
Crossref
Crossref
Mathieu S. Bolhuis, Prashant N. Panday, Arianna D. Pranger, Jos G. W. Kosterink & Jan-Willem C. Alffenaar. (2011) Pharmacokinetic Drug Interactions of Antimicrobial Drugs: A Systematic Review on Oxazolidinones, Rifamycines, Macrolides, Fluoroquinolones, and Beta-Lactams. Pharmaceutics 3:4, pages 865-913.
Crossref
Crossref
Myke R. Green & Joseph E. Woolery. (2011) Optimising absorption of posaconazole. Mycoses 54:6, pages e775-e779.
Crossref
Crossref
Russell E. Lewis. (2011) Current Concepts in Antifungal Pharmacology. Mayo Clinic Proceedings 86:8, pages 805-817.
Crossref
Crossref
Russell E Lewis. (2011) Pharmacokinetic–pharmacodynamic optimization of triazole antifungal therapy. Current Opinion in Infectious Diseases 24, pages S14-S29.
Crossref
Crossref
Sandrine Lefeuvre, Mohammed-Larbi Jelassi, Amine Benlmouden, Maud Berge, Chantal Le Guellec & Eliane M. Billaud. (2011) Niveau de preuve du suivi thérapeutique pharmacologique du posaconazole. Therapies 66:2, pages 115-122.
Crossref
Crossref
Hans-Peter LippDrDr. (2011) Posaconazole: clinical pharmacokinetics and drug interactions. Mycoses 54, pages 32-38.
Crossref
Crossref
Paul O. Gubbins & Jarrett R. Amsden. 2011. Drug Interactions in Infectious Diseases. Drug Interactions in Infectious Diseases
509
560
.
Russell E. Lewis & David S. Perlin. 2011. Principles and Practice of Cancer Infectious Diseases. Principles and Practice of Cancer Infectious Diseases
317
329
.
David R. Andes & William E. Dismukes. 2011. Essentials of Clinical Mycology. Essentials of Clinical Mycology
61
93
.
Ashraf S. Ibrahim, John E. EdwardsJrJr, Scott G. Filler & Brad Spellberg. 2011. Essentials of Clinical Mycology. Essentials of Clinical Mycology
265
280
.
Michael PfallerJeniel Nett & David Andes. 2010. Kucers' The Use of Antibiotics Sixth Edition. Kucers' The Use of Antibiotics Sixth Edition
1862
1870
.
Hans-Peter Lipp. (2010) Clinical pharmacodynamics and pharmacokinetics of the antifungal extended-spectrum triazole posaconazole: an overview. British Journal of Clinical Pharmacology 70:4, pages 471-480.
Crossref
Crossref
Russell E. Lewis. (2010) Antifungal Therapeutic Drug Monitoring. Current Fungal Infection Reports 4:3, pages 158-167.
Crossref
Crossref
Elizabeth Dodds‐Ashley. (2012) Management of Drug and Food Interactions with Azole Antifungal Agents in Transplant Recipients. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 30:8, pages 842-854.
Crossref
Crossref
Ashley Bartell, Arti Phatak, Kirsten Horn & Michael Postelnick. (2010) Drug Interactions Involving Antifungal Drugs: Time Course and Clinical Significance. Current Fungal Infection Reports 4:2, pages 103-110.
Crossref
Crossref
Paul O. Gubbins & Seth Heldenbrand. (2010) Clinically relevant drug interactions of current antifungal agents. Mycoses 53:2, pages 95-113.
Crossref
Crossref
Marie-Clémence Verdier, Danièle Bentué-Ferrer, Olivier Tribut & Eric Bellissant. (2010) Liquid chromatography-tandem mass spectrometry method for simultaneous quantification of four triazole antifungal agents in human plasma. Clinical Chemistry and Laboratory Medicine 48:10.
Crossref
Crossref
Dominik Schrey, Thomas J. Walsh & Andreas H. Groll. 2010. Side Effects of Drugs Annual 32 - A worldwide yearly survey of new data and trends in adverse drug reactions and interactions. Side Effects of Drugs Annual 32 - A worldwide yearly survey of new data and trends in adverse drug reactions and interactions
491
519
.
Dustin T. Wilson, Richard H. Drew & John R. Perfect. (2009) Antifungal Therapy for Invasive Fungal Diseases in Allogeneic Stem Cell Transplant Recipients: An Update. Mycopathologia 168:6, pages 313-327.
Crossref
Crossref
Elizabeth Dodds Ashley. 2009. Antifungal Therapy. Antifungal Therapy
199
218
.
Gopal Krishna, A Moton, L Ma, M Martinho, M Seiberling & J McLeod. (2009) Effects of Oral Posaconazole on the Pharmacokinetics of Atazanavir Alone and With Ritonavir or With Efavirenz in Healthy Adult Volunteers. JAIDS Journal of Acquired Immune Deficiency Syndromes 51:4, pages 437-444.
Crossref
Crossref
Michele I. Morris. (2009) Posaconazole: A new oral antifungal agent with an expanded spectrum of activity. American Journal of Health-System Pharmacy 66:3, pages 225-236.
Crossref
Crossref
Paul O. Gubbins & Elias J. Anaissie. 2009. Clinical Mycology. Clinical Mycology
161
195
.
Russell E. Lewis. 2008.
Aspergillus fumigatus
and Aspergillosis
.
Aspergillus fumigatus
and Aspergillosis
445
456
.
Erik J Rachwalski, Jeffrey T Wieczorkiewicz & Marc H Scheetz. (2008) Posaconazole: An Oral Triazole with an Extended Spectrum of Activity. Annals of Pharmacotherapy 42:10, pages 1429-1438.
Crossref
Crossref
L. J. Worth, C. C. Blyth, D. L. Booth, D. C. M. Kong, D. Marriott, M. Cassumbhoy, J. Ray, M. A. Slavin & J. R. Wilkes. (2008) Optimizing antifungal drug dosing and monitoring to avoid toxicity and improve outcomes in patients with haematological disorders. Internal Medicine Journal 38:6b, pages 521-537.
Crossref
Crossref
Renee M. Fallon & Jennifer E. Girotto. (2008) A Review of Clinical Experience with Newer Antifungals in Children. The Journal of Pediatric Pharmacology and Therapeutics 13:3, pages 124-140.
Crossref
Crossref
James E Frampton & Lesley J Scott. (2008) Posaconazole. Drugs 68:7, pages 993-1016.
Crossref
Crossref
Paul O Gubbins. (2007) Mould-active azoles: pharmacokinetics, drug interactions in neutropenic patients. Current Opinion in Infectious Diseases 20:6, pages 579-586.
Crossref
Crossref
Silke C. Müller & Tobias Welte. (2007) Arzneimittel-Interaktionen mit systemischen Antimykotika beim IntensivpatientenDrug interactions with systemic antimycotics in intensive care patients. Intensivmedizin und Notfallmedizin 44:8, pages 526-534.
Crossref
Crossref